All compounds

Once-weekly GLP-1 receptor agonist for diabetes and obesity.

Hormone replacement for hypogonadal men; widely used off-label for performance and body composition.

Dual GLP-1/GIP agonist with A-grade evidence — the standard-of-care anchor for the modern incretin era.

Oral ghrelin receptor agonist that raises GH and IGF-1; investigated for sarcopenia.

Melanocortin receptor agonist approved for hypoactive sexual desire in premenopausal women; off-label male use widespread.

mTORC1 inhibitor with the strongest longevity evidence of any pharmacologic in mammals.

Long-acting GHRH analog approved for HIV lipodystrophy; off-label use for body composition and visceral fat.

Thymic peptide approved in some countries for hepatitis and immune modulation.

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

NOT a Peptide — A Synthetic Heterocyclic Amine. Zero Human Clinical Trials. The Most Compelling In Vitro Dopaminergic Neuroprotective Profile in the Nootropic Space. Also a MAO-A Inhibitor (IC50 = 1 μM) With Tyramine Reaction and Serotonin Syndrome Risk. Also a Photosensitizer With UV-Activated DNA Damage Potential. The Most Dangerous Safety Profile of Any Nootropic in This Book.

A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

Engineered to Not Be EPO. Proven to Regenerate Nerves in Humans. WADA Banned Anyway. And the Company That Made It No Longer Exists.

NOT a Peptide — An Oral Small Molecule Drug in Active Phase 1b/2 Clinical Development. Formerly O-304 (Betagenon). Now ATX-304 (Amplifier Therapeutics / Cambrian Bio). Pan-AMPK Activator + Mitochondrial Uncoupler. Exercise Mimetic. Phase 2a Human Data: Significant Fasting Glucose Reduction in T2D. Multiple Strong Animal Studies: Fat Loss, MASLD, Cardiovascular, Kidney Protection. The Most Clinically Advanced Novel Compound in This Book.

The Mitochondrial Uncoupler That Doesn't Kill You. DNP Kills People in 2026. BAM15 Was Designed to Solve That. Fat Loss Without Hyperthermia. Without Reduced Food Intake. Without Lean Mass Loss. Without Toxicity Markers. In Mice. Nature Communications 2020. Zero Human Trials. The Most Mechanistically Elegant Fat Loss Compound in This Book — and the Most Preclinical.

544 Papers, 30 Years, One Lab — The Healing Peptide with the Most Research and the Least Independent Evidence

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

GlaxoSmithKline Halted Their Own Drug in 2007 Because It Caused Cancer in Every Animal Species They Tested. The Community Is Still Using It. The Drug Worked. That Is the Entire Problem.

More Clinical Trial Data Than Almost Anything in This Book. Approved in Over 40 Countries. The Largest Independent RCT Failed Its Primary Endpoint. Every Major Positive Trial Has the Manufacturer's Name in the Author List. Cochrane Says: Low to Very Low Evidence.

The Most Common Community GHRH Analog — Sold Under Three Names. The DAC Confusion That Has Been Causing Purchasing Errors for a Decade. Why DAC Changes Everything About the Dosing Protocol. The Four Substitutions That Make Mod GRF 1-29 Last Long Enough to Work. How the GHRH Receptor and GHS-R1a Receptors Synergize. Why Teichman 2006 Actually Studied CJC-1295 WITH DAC — Not This Compound. The Empty Stomach Rule Is Not Optional.

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

The Only Senolytic With Real Human Trial Data. Tested at the Mayo Clinic. Proven to Clear Senescent Cells in Humans. Dasatinib Is a Chemotherapy Drug. The Community Is Using It Without Prescriptions, ECGs, or Drug Interaction Screens.

Reported to Be 10 Million Times More Potent Than BDNF. The Foundational Mechanistic Data Is Under a Research Integrity Cloud. The Clinical Prodrug Failed Phase 2/3. The Community Uses It Anyway.

Isolated 1977. Named for Sleep. 40+ Years of Research. No Gene Found. No Specific Receptor Identified. Half-Life 15 Minutes In Vitro — Yet Produces Multi-Night Effects. Studied for Sleep, Stress, Alcohol Withdrawal, Opiate Withdrawal, Neuroprotection, and Longevity. The Most Mechanistically Mysterious Compound in This Book.

Eli Lilly's Selective Amylin Receptor Agonist. The Most Recent Lancet Publication in This Book (December 2025). Phase 2 Completed August 2025: 9.5-20.1% Weight Loss vs 0.4% Placebo at 48 Weeks. Phase 3 Just Started Enrollment (December 2025). The AMY1R-Selective Design: 12x More Selective for AMY1R vs CTR — Potentially Addressing the Two Biggest Limitations of Non-Selective Amylin Agonists (Nausea and Medullary Thyroid Carcinoma Risk). Lilly's Amylin Answer to Tirzepatide's GIP Addition.

The Pure Active Isomer in Clomid. The Drug That Raised Testosterone as Well as TRT While Preserving Fertility — and Still Failed FDA Approval. The Zuclomiphene Problem: Why the Racemic Mixture Causes Side Effects Pure Enclomiphene Shouldn't. The NDA That Died in 2021. How It Differs from TRT, HCG, and Gonadorelin for Male Hypogonadism. The 2025 Meta-Analysis: +273 ng/dL Testosterone vs Placebo.

40 Years of Research From One Lab. The Most Cited Telomere Peptide in the Longevity Space. The First Independent Replication Was Published in 2025.

The World's Best-Selling Senolytic Supplement. One Landmark Mouse Study. One ITP Failure. Multiple Human Trials Running for Years With No Published Senolytic Endpoint Data. The Bioavailability Problem Nobody in the Marketing Ecosystem Discusses.

A 2017 Paper Showed It Extended Mouse Lifespan by 24.8%. The Community Is Already Injecting It. There Has Never Been a Human Safety Trial. And It Works by Interfering With p53.

NOTE: This chapter covers GHK as a free tripeptide — its endogenous biology, copper-carrier function, and primary topical cosmetic applications. The systemic, injectable, and regenerative applications of the copper-chelated complex are covered in the GHK-Cu chapter, which should be read alongside or before this chapter. Plasma Levels: 200 ng/mL at Age 20, Declining to 80 ng/mL by Age 60. The Connectivity Map and 4,000 Genes. Loren Pickart (1938–2023). The Copper Switch.

The Body's Own Repair Signal — And the Evidence Gap Between What It Does and How People Use It

Zero Published Human RCTs for the Injectable Route. Every Protocol is Extrapolated from Topical and Animal Data. The Anela Protocol: The Community Standard Defined. ISR Management: Why 3mL/50mg is the Standard Dilution. Copper Accumulation Risk on Long Cycles. The Systemic Healing Signal: Animal Evidence That Injected GHK-Cu Heals at Remote Sites. The Active Malignancy Hard Stop. Reconstitution Guide. Stacking with BPC-157 and TB-500 in the GLOW Protocol.

8+ Human RCTs on Topical Application. The Compound That Outperformed Vitamin C and Retinoic Acid for Collagen Deposition. Leyden 2002: 67% Reduction in Wrinkle Volume at 12 Weeks. Yuvan 2023: +28% Skin Collagen Density by Dermal Ultrasound. The Active Malignancy Contraindication Applies Regardless of Route. The Route Gap That Makes This Chapter Necessary: Topical Evidence Is Not Evidence for Injectable. See GHK-Cu (Injectable) for the Zero-RCT Community Protocol.

The Most Potent Injectable GHRP. Japan-Approved as a Diagnostic Agent. WADA S2 Banned. The Cortisol Problem That Cuts Against What You're Using It For. The Compound the Community Has Mostly Moved Past — and Why Understanding It Anyway Matters.

The Original GHRP — Discovered 12 Years Before the Receptor It Activates Was Named. The Compound That Proved the Ghrelin System Existed Before Ghrelin Was Found. Why Every Subsequent GHRP Was Designed to Fix GHRP-6's Problems. The Hunger That Arrives in 20 Minutes. Cortisol and Prolactin: How Much, Why It Matters, When to Care. The Unexpected Cytoprotective Signal Via CD36. Why Some Bulkers Prefer It Over Ipamorelin on Purpose.

The Nobel Prize Decapeptide (Schally and Guillemin, 1977). The Compound That Is Stimulatory When Pulsatile and Suppressive When Continuous — From the Same Receptor. The Most Pharmacologically Nuanced Chapter in This Book. Why the FDA's March 2020 HCG Compounding Ban Changed TRT Practice Overnight. Gonadorelin vs HCG: The Fertility Preservation Head-to-Head. Why FSH Matters for Spermatogenesis. The Pulsatile Dosing Problem in Practice.

The Compound Every Secretagogue in This Book Targets. 191 Amino Acids. FDA-Approved for GH Deficiency, HIV Wasting, Short Bowel Syndrome. July 2025: Skytrofa Once-Weekly Now Approved for Adults. The Pulsatile vs Continuous GH Exposure Distinction. IGF-1 as the Surrogate Marker. The Fake HGH Crisis. WADA S2 Absolute Ban. Why Secretagogues (Sermorelin, Ipamorelin, MK-677) Are Different. The Active Malignancy Hard Stop. The Cancer-IGF-1 Question That Never Goes Away.

FDA-Approved for Fertility and Male Hypogonadism. The Most Important Hormone in Post-Cycle Therapy. The Active Ingredient in the Simeons 500-Calorie Diet — a Fraud With Its Own FDA Warning. WADA S2 Banned. A Tumor Marker. Three Completely Different Identities in One Glycoprotein.

Found in Surviving Brain Cells of an Alzheimer's Patient. Encoded in Mitochondrial DNA. Higher in Centenarians' Children. Inversely Correlated With IGF-1. The GH Axis the Community Raises for Anti-Aging Suppresses It.

Designed as a Research Tool to Bypass IGFBP Regulation. ~100-Fold Reduced Binding-Protein Affinity. 20-30 Hour Half-Life vs IGF-1's 10-15 Minutes. The Most Potent IGF-1 Analog Available. No Controlled Human Trial for Body Composition. No Tumor Selectivity. WADA S2 Banned. A Compound Whose Full Cancer Risk Is Genuinely Unknown.

The Compound Defined by What It Doesn’t Do. Every GHRP Before It Elevated Cortisol and Prolactin. Ipamorelin Was Designed to Produce a Clean GH Pulse Without HPA Axis Activation. Raun et al. 1998: 'The First Selective Growth Hormone Secretagogue.' Why the Community Switched From GHRP-6 to Ipamorelin for Most Applications. The GH Stack Partner. The Empty Stomach Rule. Why Selectivity Matters in Practice.

The Drug That Reversed Brain Aging in Mice. Discovered by Phenotypic Screen. Target Unknown for 7 Years. ATP Synthase: The Unexpected Bridge Between Alzheimer's and Aging. BDNF Induction. AMPK/mTOR via a Completely Novel Entry Point. Phase 1 Human Safety Trial Completed (NCT03838185). The Compound That Is Structurally Related to Curcumin But Pharmacologically Nothing Like It.

Four Organ-Specific Bioregulators from the Russian Khavinson Research Tradition. The Theory That Short Peptides Regulate Gene Expression in a Tissue-Specific Way. Cortexin: A Russian-Approved Neuroprotective Extract with Multi-Receptor Activity. CardioCytogen (Ala-Glu-Asp-Arg): The Cardiac Fibroblast Modulator. Crystagen: Connective Tissue and Cartilage Bioregulator. Bronchogen: Pulmonary Bioregulator Tetrapeptide. The Shared Evidence Architecture That Applies to All Four.

40+ Years of Russian Research. 500+ Publications. One Institution. The Most Concentrated Single-Lab Provenance of Any Compound Class in This Book. Vladimir Khavinson (1946-2024) and the St. Petersburg Institute of Bioregulation and Gerontology. The Epigenetic Chromatin Mechanism. The Cytomax vs Cytogen Distinction. The 6-to-8-Year Mortality Study. The 2025 Independent Replication That Changed the Evidence Conversation. 14 Organ-Specific Bioregulators — Their Sequences, Targets, Evidence, and Protocols.

Named After Hershey's Kisses. Discovered as a Metastasis Suppressor Gene. Repurposed as the Master Upstream Regulator of the Entire HPG Axis. The Most Potent Known Activator of GnRH Neurons. Human Clinical Trials in Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea, IVF Triggering, and Hypoactive Sexual Desire Disorder. Limbic Brain Activation Proven by fMRI. No FDA Approval. The Most Pharmacologically Compelling Compound in PCT That No One Has Properly Studied for PCT.

Alpha-MSH's Anti-Inflammatory Fragment — And It May Work Completely Differently Than Everyone Thinks

NOT a Peptide — An Amino Acid Quaternary Ammonium Compound. The Most Commercially Overstated Compound in This Book. Genuine Grade B Evidence for Neuropathy (ALCAR), Peripheral Artery Disease (PLCAR), Muscle Recovery (LCLT), Male Infertility (L-Carnitine), and Post-MI Cardiac Outcomes. The TMAO Safety Question. Why Using the Wrong Form Explains Half the Negative Trials. FDA-Approved for Dialysis-Related Carnitine Deficiency.

Every Cell Makes It. Every Major Disease Depletes It. Oral Supplementation Below 1% Bioavailability in Standard Form. IV Delivery With Documented Fatalities. A Billion-Dollar Skin Whitening Industry Built on Mixed Evidence. The Precursor Strategy That Outperforms the Molecule Itself.

The Most Phase-1-Tested SARM in History. The Problem: Phase 1 Used 0.1-1 mg. The Community Uses 5-20 mg. +1.21 kg Lean Mass at 1 mg in 21 Days. Phase 2 Hip Fracture Trial Positive. HPTA Suppression Dose-Dependent and Documented in Clinical Data. The Dose Gap Between Clinical Trials and Community Use Is the Central Risk Issue. Multiple Elite Athlete Doping Violations Including Canelo Álvarez. WADA S1.2.

NOT a Single Molecule — A Compounded Formulation That Varies by Pharmacy. The Most Commercially Prominent Injectable in Weight Loss Clinics. Zero RCTs for the Combination as a Weight Loss Intervention. Strong Component-Level Evidence for Inositol in PCOS/Insulin Resistance (Oral). Legitimate Bioavailability Advantage for B12 Injection in Deficiency Only. The Injection That Is More Psychologically Than Pharmacologically Distinctive.

⚠ NAMING COLLISION: 'Lipo-C' is used for TWO completely different products — this chapter covers the compounded MIC+L-Carnitine+B-vitamins lipotropic injection. Liposomal Vitamin C (a separate oral supplement also called 'Lipo-C') is covered in a separate chapter. Read Section 1 before proceeding. Lipo-B Extended: Adds L-Carnitine, Thiamine (B1), and Dexpanthenol (B5) to the Lipo-B MIC+B12 base. Zero RCTs for the combination. L-Carnitine Injectable Dose is 100-200x Below Oral Therapeutic Doses. Mechanistically Coherent. Clinically Unproven.

The Only Human Cathelicidin. Antimicrobial, Anti-Biofilm, Pro-Angiogenic, Immunomodulatory, Wound-Healing. Phase IIb Clinical Evidence in Chronic Wounds. Overexpressed in Rosacea, Ovarian Cancer, Breast Cancer, Lung Cancer, Melanoma. Tumor-Suppressive in Colon and Gastric Cancer. The Most Contextually Bidirectional Compound in This Book. Vitamin D Is Its Most Important Natural Inducer.

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

FDA-Approved. EMA-Approved. The First Effective Treatment for a Disease That Traps Patients Indoors. The Compound That Tans Without UV. The Nevi Darkening Warning the Community Ignores. The Melanoma Question That Has No Clean Answer. The Widest Gap in This Book Between the Disease It Was Made For and the Use It Is Actually Known For.

One Molecule That Tans Your Skin, Triggers Erections, Suppresses Appetite, and Elevates Blood Pressure — All Through Different Receptors on the Same Injection. The University of Arizona Drug That Spawned PT-141. Why the 'Barbie Drug' TikTok Trend Is the Most Dangerous Community Use Pattern in This Book. The Melanoma Question: Four Case Reports, Two Conflicting Reviews, and One Confound. Rhabdomyolysis at 12x the Starting Dose. What the Nasal Spray Market Actually Contains.

The TAME Trial: The First FDA-Recognized Study to Use 'Aging' as a Drug Indication. The Bannister Study: Diabetics on Metformin Outlive Non-Diabetics. The 2024 Cell Primate Paper: 6.1-Year Brain Aging Regression. The Exercise Controversy: Metformin Blunts the Mitochondrial Benefits of Training. B12 Depletion: The Most Important Long-Term Safety Issue. Metformin vs Rapamycin: The Same mTOR Pathway, Different Entry Points. Who Benefits Most. Who Shouldn't Use It.

The Soviet-Era Parkinson’s and Depression Compound Hiding in Limitless’s Catalog. A Tripeptide That Blocks Opioid Effects, Sensitizes D2 Dopamine Receptors, and Has a 5-Day Plasma Half-Life. The Research That Ceased When the Soviet Union Collapsed. What the 2010 Khan et al. Brain Activation Paper Actually Found. NOT the Same as MIF (Macrophage Migration Inhibitory Factor). Why “Melanocyte-Inhibiting Factor” Is a Historical Misnomer.

The Only Oral Compound in This Book That Reliably Raises GH and IGF-1. GHSR-1a Agonist: Not a SARM. The Merck Story: Six Indications, No NDA, Program Discontinued. IGF-1 Goes Up. Fat-Free Mass Goes Up. Strength Doesn't Follow. Glucose Does Go Up. Appetite Definitely Goes Up. The CHF Signal in Elderly Patients. FDA October 2024 PCAC: No Compounding. WADA S2. The Water Weight Trap. Why Sleep Quality Is the Most Reliable Benefit. The Community's Most Misunderstood Compound.

The Compound Synthesized in 2024 That Vendors Claim Is Superior to MK-677. 92% Higher Binding Affinity, 18-22 Hour IGF-1 Elevation, Fluorinated Backbone for Metabolic Stability — According to Vendor Specifications. What Independent Published Research Actually Exists: Essentially None. How to Use MK-677’s Clinical Evidence as the Pharmacological Framework While Being Honest That MK-777’s Specific Properties Are Unvalidated. WADA S2. Limitless Capsules.

Mitochondrial-derived peptide with metabolic and exercise-mimetic effects in animal models.

The Exercise-Mimetic Peptide Encoded in Mitochondrial DNA — Revolutionary Biology, Zero Human Intervention Trials, WADA Banned at All Times.

The Drug That Was Going to Treat Leaky Gut and Celiac Disease — And How the Phase 3 Trial Ended. What Zonulin Actually Is and Why Tight Junction Regulation Is Hard to Measure. Four Phase 2 RCTs: Symptom Improvement With Gluten Challenge. The Phase 3 Discontinuation in 2022. The N-Acetyl Modification That Limitless Sells: What It Adds and What It Doesn’t Change. How This Differs From BPC-157 and KPV in the Gut Stack.

Tuftsin → Selank → N-Acetyl Selank Amidate: Three Generations of Molecular Engineering. Russian-Approved Anxiolytic Without Sedation, Without Tolerance, Without Dependence. Comparable to Benzodiazepines for GAD With Psychostimulant Properties They Lack. BDNF Upregulation. Enkephalin Stabilization. The Evidence Is for Selank. NASA Is the More Stable Delivery Format Whose Equivalent Efficacy Is Chemically Logical but Clinically Unproven.

ACTH Fragment Without the Cortisol Effect. Russia's Premier Nootropic-Neuroprotective Peptide. Approved for Stroke, Encephalopathy, Optic Nerve Atrophy, Cognitive Disorders. BDNF Upregulation 50-300% in Hippocampus and Frontal Cortex. Default Mode Network Changes by fMRI. 71% vs 41% Memory Test Accuracy in Fatigued Volunteers. Half-Life Extended from 3-5 Minutes (Semax) to 4-6 Hours (MASA) by N-Acetyl and Amidate Modifications.

The Maximally-Modified Form of Semax, Built by the Community Rather Than a Pharmaceutical Company. What N-Acetylation Actually Does to a Peptide at the Molecular Level. What C-Terminal Amidation Actually Does. Why These Two Modifications Together Are Different from Either Alone. The Evidence Problem: Everything Below Is Extrapolated from Semax. NOT the Same as NA Selank Amidate (Adamax). Limitless Spray Format. Why Morning Dosing Is Not Optional.

This addendum expands the NAD+ chapter with a dedicated section on subcutaneous injectable NAD+ — covering pharmacokinetics, why SubQ differs from oral precursors and IV infusion, reconstitution from lyophilised vials, injection technique, dose titration, side effect management, and the honest evidence comparison with oral NMN/NR and IV administration.

The Most Legitimate Longevity Target in This Book. The Most Commercially Weaponized. The Man Promoting NMN Has Financial Ties to NMN. The Man Criticizing Him Has Financial Ties to NR. The Clinical Evidence Is Real and More Modest Than Either Side Tells You.

NAD+ precursor supplement; raises blood NAD+ levels reliably but functional benefits in humans remain unclear.

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

The Compound That Is 1,000x More Potent Than Piracetam by Weight. The Prodrug Whose Active Metabolite Is Endogenous to the Human Brain. Phase III Clinical Trials Exist — In Russian. Russian OTC Approval Since 2006 — Based on Real Trials That Western Evidence-Based Reviewers Cannot Read. Why It Is Not a Racetam Despite What Everyone Says. Cycloprolylglycine: The Metabolite That Does the Work. Enhanced Dreams as a Pharmacological Signal. The Dose Ceiling That Most Community Users Ignore.

The First True Oral GLP-1: Take It Anytime, With or Without Food, No Injection. ATTAIN-1 (NEJM 2025; n=3,127; 72 Weeks): -11.2% Body Weight at 36mg. Why Small Molecule Matters: The Chemistry That Makes This Pill Possible When No Peptide Could Be. Orforglipron vs Oral Semaglutide vs Injectable GLP-1s: The Efficacy-Accessibility Trade-Off. ATTAIN-MAINTAIN: It Maintains Weight Loss After Switching Off Wegovy and Zepbound. Why This Compound Changes Who Gets GLP-1 Therapy.

The Most Clinically Studied SARM. The Phase 3 Trials That Nearly Got It Approved. Why the FDA Said No — and Why It Matters. The Most Modest HPTA Suppression Profile in the SARM Class. The Lowest Hepatotoxicity Signal. The Closest Any SARM Has Come to an FDA Indication. Why Phase 3 Failure Doesn't Mean the Compound Doesn't Work. Jonas Brodin and the NHL Doping Case.

The First Peptide Ever Synthesized (Nobel Prize 1955). FDA-Approved for Obstetric Use Since the 1950s. The 'Love Hormone' That Science Has Substantially Complicated. Intranasal Bioavailability ~2%. Trust Enhancement Replication Failures. Autism Trials: Mixed to Null. Context-Dependent Effects That Can Go Either Direction. And an OTC Nasal Spray Industry Built on Evidence That Doesn't Support What It Claims.

The 7-Amino-Acid Antidepressant That Works in 4 Days Instead of 4 Weeks. TREK-1: The Potassium Channel That Keeps You Depressed. IC50 of 0.12 nM — 333x More Potent Than Its Parent Spadin. Duration Extended to 23 Hours vs 7 Hours. Hippocampal Neurogenesis in 4 Days. The Same One French Research Group Since 2010. Zero Human Trials. A Novel Mechanism That Bypasses the Serotonin Transporter Entirely.

Cancer-Selective Membrane Pore Formation. MDM2 on the Surface of Cancer Cells as the Target. No Phase 1 Human Trials. No FDA Review. No Human Safety Data. Used by Cancer Patients as Last Resort. The Most Ethically Complex Chapter in This Book. What the Evidence Actually Shows. What It Cannot Show. Why Active Cancer Patients Must Read This Chapter Before Any Self-Administration Decision.

The Compound Designed to Kill Cancer Cells by Forming Pores in Their Membranes. The Reversal: Active Malignancy Is the Designed Use Context. How MDM2 on Cancer Cell Surfaces Creates the Selectivity Mechanism. p53 AA17-26 + Penetratin: What Each Domain Does. PNC-27 vs PNC-28: The Structural Difference and Whether It Matters. In Vitro Human Cancer Cell Data and In Vivo Mouse Model Evidence. The Community Off-Label Use Question.

The Only FDA-Approved Peptide in This Book — Approved for Women, Used Primarily by Men, for Different Reasons, With Different Evidence.

The Selectivity Claim That Doesn't Hold Up in the Only Published Human Trial. Phase 1 Breast Cancer Study: 59% Elevated AST, 45% Elevated ALT. Six or More Published DILI Case Reports — Including Near-Transplant Cholestatic Hepatitis. HPTA Suppression: As Real as Testosterone. WADA S1.2 Absolute Ban. FDA Warnings. The 53% Problem: Only Half of SARM Products Contain What They Claim. Why 'Fewer Side Effects Than Steroids' Doesn't Mean Safe.

The ITP Mouse Data: Lifespan Extended at Multiple Labs, Doses, and Start Ages. The PEARL Trial (April 2025): First 48-Week Placebo-Controlled Human Longevity Trial Published. The Bioavailability Finding That Changes Everything: Compounded Rapamycin Is ~3x Less Bioavailable Than Commercial. Intermittent vs Continuous Dosing: The Pharmacological Divide Between Transplant Medicine and Longevity Use. The Immunosuppression Risk That Needs Honest Framing. The Drug Interaction Profile That Makes This the Most Dangerous Compound in This Book to Stack. Why the Community Uses ~6 mg Weekly. What Happens When You Stop.

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

Russia Approved It. The West Has Never Independently Validated It. And It Might Be the Only Anxiolytic That Doesn't Make You Stupid.

The Drug That Extended Rat Lifespan in 1988 and Still Fascinates the Longevity Community. Irreversible MAO-B Inhibitor. Dopamine Preservation. BDNF Upregulation. The DATATOP Trial: Symptomatic Effect, Not Neuroprotection — The Distinction That Matters. The Amphetamine Metabolites: L-Enantiomers Only — What That Means Clinically. Low-Dose Community Protocols (1-5 mg Every Few Days). Why High-Dose Loses MAO-B Selectivity and What Happens Then. Selegiline vs Rasagiline. The Cheese Reaction: When It Applies and When It Doesn't.

The Only FDA-Approved Drug in This Book. The Most Prescribed Drug in Human History. STEP Program: -14.9% Body Weight at 68 Weeks. SELECT Trial: 20% Reduction in Major Cardiovascular Events. Grade A Evidence Across the Broadest Human Trial Program of Any Compound in This Book. The Weight Rebound Question: 2/3 of Weight Returns Within 1 Year of Stopping in Controlled Trials. The Compounded Semaglutide Regulatory Crisis. What the Real-World Data Actually Shows About Discontinuation.

Russia Uses It for Stroke. The West Uses It for Morning Focus. The Evidence Is Strong for One of Those. Guess Which.

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.

The Compound Designed for Patients Whose Brains Literally Cannot Signal 'Stop Eating.' The POMC/LEPR/PCSK1 Pathway Explained: Why These Patients Gain Weight from the Day They Are Born. 80% Achieved ≥10% Weight Loss in the POMC Trial. 51 kg Lost in a Single Patient in Phase II. The Off-Label Question: Does It Work When the Pathway Is Intact? Why 78% of Patients Develop Skin Hyperpigmentation — and Why That Is Not the Same Risk as Melanotan II. vs MT-II: Same Receptor Family, Opposite Selectivity Approach.

The Metabolically Active Member of a Six-Peptide Family From the Same Mitochondrial Gene as Humanin. A Receptor Has Been Found. An Obesity Protection Mechanism Has Been Identified. Lower Levels Are Associated With Prostate Cancer Risk. No Human Trial Has Been Run.

Every Other MDP in This Book Keeps Cells Alive. SHLP6 Tells Them to Die. This May Be Exactly the Point — and the Most Underappreciated Mechanism in the Entire Mitochondrial Peptide Family.

Not a Peptide. 70% Endurance Gain in Mice. Zero Human Trials. WADA Banned Before Anyone Had Studied It in a Human.

Topical Cosmeceutical ONLY — NOT Injectable. Argireline Extended by Two Amino Acids. Targets the Same SNARE Complex as Botulinum Toxin — Via a Completely Different and Far Weaker Mechanism. The Penetration Problem: <0.2% of Applied Peptide Crosses the Stratum Corneum Passively. The 63% Claim: Manufacturer-Sponsored, 17 Subjects, Not Independently Replicated. Microneedle Delivery Genuinely Improves Outcomes. Dynamic Wrinkles Only.

SS-31's Sister Compound. Targets the Same Mitochondrial Membrane. Cannot Scavenge Free Radicals. Works Anyway. Which Proves Something Important About How SS-31 Actually Works.

The Only FDA-Approved Mitochondrial Therapeutic. Most Clinical Trials Failed. The Basic Science Is Compelling. All Three of These Things Are True Simultaneously.

The CIT Blend runs two GHRH analogs simultaneously — CJC-1295 (no-DAC) and Tesamorelin — plus Ipamorelin. The pharmacological question: can two GHRH analogs produce additive GHRH receptor activation, or does the first compound substantially saturate the receptor such that the second adds minimal additional GH release? GHRH receptor dynamics (occupancy, Gq coupling, downstream amplification) determine whether this is additive, synergistic, or redundant. No published study addresses this question for the specific CJC-1295 + Tesamorelin combination. Community clinical practice from the Peptide Partners context suggests value; the mechanistic basis for why two GHRH analogs would produce additive rather than saturating effects is not established. Tesamorelin may contribute through mechanisms beyond pure GHRH receptor activation — including direct adipocyte effects that CJC-1295 alone may not produce at the same magnitude. This remains an open pharmacological question.

The GH Stack has better mechanistic and clinical supporting evidence than any other stack in this book. The GHRH+GHRP synergy is replicated across species, multiple compound pairs, and over 30 years of research. CJC-1295 has Phase 1/2 human trial data (Teichman 2006: IGF-1 elevation +35-120% dose-dependent). Ipamorelin's selectivity advantage (no cortisol, no prolactin, no ACTH) was demonstrated in human pharmacology by Raun et al. (1998). The central tension is not evidence quality — it is the DAC distinction. A significant portion of community users receive or purchase CJC-1295 WITH DAC believing it is equivalent to CJC-1295 without DAC. It is not. DAC fundamentally changes the pharmacology from pulsatile to sustained — producing receptor desensitization and blunting natural GH pulsatility rather than enhancing it. Getting the DAC question right is the most important practical element of this chapter.

The GLOW Stack adds GHK-Cu's copper-mediated collagen remodeling to the Wolverine healing foundation — a mechanistically logical addition that addresses what Wolverine doesn't: ECM organization and cosmetic tissue quality. The tension: adding GHK-Cu adds the injectable copper safety considerations (active malignancy hard stop, Wilson disease contraindication, copper accumulation risk on long cycles) to the stack's risk profile. The active malignancy hard stop for GHK-Cu applies to the entire GLOW Stack — the other two components have a 'caution' signal for malignancy, but GHK-Cu elevates the whole stack to a hard stop. Additionally, the blended vial format (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500) fixes the 5:1:1 ratio regardless of individual dosing preferences — understanding when this ratio is appropriate and when separate vials are better is the practical core of this chapter.

The Gut Stack's central tension is not evidence quality — it is scope appropriateness. BPC-157 oral is appropriate for gut; BPC-157 oral is not appropriate for joint and tendon healing (doesn't achieve systemic levels). KPV as a standalone anti-inflammatory is compelling but understudied in humans — the clinical evidence comes primarily from IBD models and alpha-MSH pathway research, with the specific KPV tripeptide itself having limited independent human data. The combination therefore has a tight and well-reasoned indication (gut inflammation + mucosal repair) with honest evidence limitations (no human RCT for either compound in this specific oral combination for this specific indication). The community uses it widely for IBS, IBD-adjacent conditions, post-antibiotic gut repair, and NSAID-damaged gut mucosa — and reports consistent benefit in these contexts.

KLOW is mechanistically the most comprehensive tissue repair protocol in this book — four non-overlapping mechanisms covering angiogenesis, cell migration, ECM remodeling, and inflammatory suppression simultaneously. The tension: comprehensiveness is not the same as superiority. Adding a fourth compound means: more injections (or more complex blended vial formulation); more copper accumulation risk on extended cycles (GHK-Cu); more cost; and more moving parts when something doesn't work as expected. For many users, GLOW already covers their needs; KLOW is the right choice when the inflammatory dimension or gut protection is a specific priority. The chapter exists to clarify when KLOW is worth the additional complexity.

MOTS-c and Humanin represent a genuinely new category of biology — the mitochondrial genome encoding systemic regulatory signals beyond energy production. The pharmacological case for their combination is clean: MOTS-c targets metabolic regulation (AMPK, folate/methionine cycle, glucose uptake, exercise response); Humanin targets cellular survival (anti-apoptotic, neuroprotective, anti-inflammatory). These are non-overlapping mechanisms addressing complementary hallmarks of aging. Both decline with age. Both have animal evidence for the benefits they are claimed to produce. Both have essentially no human RCT evidence for their use as injectable peptides in community protocols. The stack sits at the intersection of genuinely interesting biology and essentially unvalidated community application.

The Wolverine Stack is the most widely used peptide healing combination in community history — thousands of user logs, years of accumulated experience, clinics prescribing it, physicians writing protocols for it. The mechanistic rationale is coherent: two compounds, two different mechanisms, two different phases of the healing cascade, administered together. And yet: BPC-157 has 36 published studies — 35 preclinical, 1 clinical. TB-500 + BPC-157 together have zero published studies of any kind. Zero. The combination that community members have been running for years has never been tested in even a mouse model as a combination. The stackGrade is C — not because the combination evidence is weak, but because the combination evidence does not exist. This chapter documents the mechanistic logic, the individual evidence bases, and what thousands of users have reported — with honest evidence framing throughout.

The Glucagon Rehabilitation Story. Phase 2 MASH (NEJM July 2024): 62% MASH Resolution vs 14% Placebo. Phase 3 SYNCHRONIZE-1 (April 2026): -16.6% Weight Loss at 76 Weeks. FDA Breakthrough Therapy for MASH September 2024. LIVERAGE Phase 3 MASH Ongoing. Why Glucagon in Metabolic Disease? The GLP-1 + GCGR Advantage Over GLP-1 + GIPR for Liver Disease. The Most Important Obesity Drug for MASH Patients That Nobody in the Community Has Heard Of.

Ketamine Without the Dissociation. Oral Once-Daily. AMPA Receptor Positive Allosteric Modulation: The Glutamate Pathway to Antidepressant Effect. Phase 2 SAVITRI (Psych Congress September 2025): Statistically Significant Improvements in Depression Severity. No Body Sway. No Subjective Drug Effects. No Dissociation. No Abuse Liability. Takeda Licensed to Neurocrine Biosciences. Phase 3 Development Horizon 2026-2027.

Discovered by Immunologists, Repurposed by Horse Trainers, and Now It May Be a Prodrug

The TB-4 Fragment That Has Nothing to Do With Actin. Why ACE Inhibitors Raise Ac-SDKP Levels — and Why That Might Explain Some of Their Anti-Fibrotic Effects. Cardiac and Renal Fibrosis Prevention in Animal Models. Produced in the Body by Prolyl Oligopeptidase Cleaving Thymosin Beta-4. The Fragment With More Published Independent Research Than Its Parent Compound. No Human RCT for Community Use.

The Fragment Every Community Vendor Sells as ‘TB-500.’ The Actin-Sequestering Domain of Thymosin Beta-4. Why the Full 43-AA Protein Is Used in Clinical Trials While the Community Uses a 7-AA Fragment. The Phase 2b Cardiac Trial That Used Full Tβ4. Whether the Fragment Recapitulates the Parent Protein’s Pharmacology. What Actin Sequestration Actually Does in Tissue Repair. Polaris and Limitless Community Formats.

The Only FDA-Approved GHRH Analog. Two Phase 3 RCTs in HIV Lipodystrophy — 15-18% Visceral Fat Reduction. A Lancet HIV NAFLD Trial Showing 37% Liver Fat Reduction and Fibrosis Prevention. A Cognitive Function Trial in Older Adults. And a Prescribing Label That Explicitly Says It Is Not a Weight Loss Drug.

NOT a Peptide — An Oral Small Molecule. Originally Developed for Alzheimer's and Parkinson's. Weight Loss Discovered as Incidental Finding. Lancet Phase 2b: 10.6% Body Weight Loss at 0.5mg (vs 2.0% Placebo). The Same +7-8 bpm Heart Rate Increase That Killed Sibutramine. The Tesomet Solution: Add a Beta-Blocker. Mexican Approval 2023. Phase 3 Ongoing. Absolute Contraindication with SSRIs and MAOIs.

The Most Referenced Compound in This Book Given Its Own Chapter. FDA-Approved for Confirmed Hypogonadism. Schedule III Controlled Substance. WADA S1 Absolute Ban. TRAVERSE Trial (NEJM 2023): TRT Does Not Increase Cardiovascular Events in Hypogonadal Men. The TTrials: Sexual Function, Bone Density, Anemia All Improved. The Central Paradox: The Compound That Is Appropriate Medical Treatment at One Baseline Testosterone Level Is Misuse at Another. Aromatization, Estradiol Management, HPTA Suppression, Testicular Atrophy, Fertility, and the Full Monitoring Protocol.

Approved in 37+ Countries. The Most Extensively Studied Thymic Peptide in Clinical Medicine. 30+ RCTs. 11,000+ Subjects. HBeAg Seroconversion RR 2.31. A Positive Sepsis Trial in 2013 Followed by a Definitive Negative Phase 3 in 2025. The US Regulatory Rollercoaster: Category 2 (2023) → Nomination Withdrawn (2024) → Pending PCAC Review (2026). Immunomodulator, Not Immunostimulant — A Critical Distinction.

The Only Thymic Hormone That Requires a Metal Cofactor. Biologically Inactive Without Zinc. The Most Important Clinical Point: Zinc Deficiency Causes Functional Thymulin Deficiency — And Zinc Supplementation Restores It. One Human Interventional Study from 1982. Extensive Animal Evidence. The Chapter That Is Also a Zinc Education.

The Most Efficacious Approved Obesity Drug in Human History. SURMOUNT-1: -22.5% at 72 Weeks. SURMOUNT-5 Head-to-Head vs Semaglutide (NEJM 2025): 20.2% vs 13.7% — 47% Greater Relative Weight Loss. GI Discontinuation Lower Than Semaglutide. The GIP Receptor Rehabilitation Story. The Weight Rebound Data. SURMOUNT-4: >25% Regain in Most Within 1 Year of Stopping. Compounded Tirzepatide FDA Status After December 2024 Shortage Removal. SURPASS-CVOT: The CV Question Semaglutide Already Answered.

NOT a Fragment of TA1 — the Full 28-Amino-Acid Thymosin Alpha-1 with an RGDR Tumor-Targeting Sequence Appended. The RGDR Motif Binds Integrin αvβ3 Overexpressed on Tumor Vasculature. A Chinese Pharmaceutical University Research Construct Designed to Concentrate TA1’s Immune Activation at Tumor Sites. What the Lao 2013 and Peng 2020 Papers Actually Show. The Community Use Question: Why a Cancer-Targeting Construct Is in General Use. What Companion Chapter pbta1v4 Covers vs What This Chapter Covers.

The Most Physiologically Broad Compound in This Book. 28 Amino Acids. Every System in the Body. VPAC1 and VPAC2. The 90-Second Half-Life Problem That Blocked IV Use. How Intranasal Administration Changed Everything. Dr. Shoemaker's CIRS Protocol: 300+ Physicians, 90%+ Symptom Reduction. The Long-COVID Connection. Aviptadil COVID ARDS Trials. The Mast Cell / MCAS Intersection. Why the Community Uses It and What the Evidence Actually Shows.

Tetrapeptide bioregulator from the Khavinson group; telomerase activation and lifespan claims rest mostly on Russian-language preclinical work.